Equivalent Dose When Converting from Spironolactone 25mg to Eplerenone in Heart Failure

Dosing Conversion Protocol

The European Society of Cardiology recommends starting eplerenone at 25mg once daily as the equivalent dose to spironolactone 25mg in heart failure patients 1, 2
Renal function and serum electrolytes should be checked before initiating eplerenone in heart failure patients 2
The target dose for both medications is 50mg once daily, but titration should be based on patient response and laboratory monitoring in heart failure patients 2

Serum potassium and renal function should be monitored closely during the transition from spironolactone to eplerenone in heart failure patients 2, 3
Follow-up laboratory testing schedule for heart failure patients converted to eplerenone includes testing at 1 week, 4 weeks, and 1, 2, 3, and 6 months after achieving maintenance dose, and every 6 months thereafter 2

For heart failure patients with reduced renal function (eGFR 30-49 mL/min/1.73m²), the American Heart Association suggests considering starting with eplerenone 25mg every other day 4
If potassium rises to >5.5 mmol/L in heart failure patients, the European Society of Cardiology recommends reducing the dose to 25mg on alternate days 2
If potassium rises to >6.0 mmol/L in heart failure patients, the European Society of Cardiology recommends stopping eplerenone immediately 2

Both medications have demonstrated mortality benefits in heart failure patients, according to the European Society of Cardiology 5, 6
Eplerenone led to a 15% relative risk reduction in death in post-MI heart failure patients (EPHESUS trial), as reported by the American College of Cardiology 5
Spironolactone showed a 30% relative risk reduction in death in severe heart failure (RALES trial), as reported by the American College of Cardiology 5

Failure to check baseline electrolytes and renal function before conversion from spironolactone to eplerenone in heart failure patients can lead to adverse effects, according to the European Society of Cardiology 2
Inadequate monitoring of potassium and renal function after conversion from spironolactone to eplerenone in heart failure patients can lead to hyperkalemia, as warned by the American Heart Association 2, 4